First new antibiotic in 50 years to tackle superbug
The drug, which targets one of the bacteria considered to pose the biggest threat to human health, has been hailed as an 'exciting' development in the fight against antibiotic resistance.
On Monday, Roche, the Swiss pharmaceutical giant, announced that it will take zosurabalpin into the third and last phase of testing on humans.
It is the first drug in five decades to show promise of tackling Acinetobacter baumannii, a pathogen which is described as a 'priority' by the World Health Organisation and an 'urgent threat' by the Centers for Disease Control and Prevention, the US national public health agency.
The drug-resistant bacteria disproportionately impact patients who are in the hospital, causing infections such as pneumonia and sepsis.
It is estimated that between 40 and 60 per cent of infected patients, many of whom are immunocompromised because of conditions such as cancer, die as a result of the bug.
One of the reasons it is so difficult to treat is that it has a double-walled 'membrane' protecting it from attack, so it is difficult to get drugs into it and to keep them in, experts say.
Zosurabalpin, which has been developed alongside researchers at Harvard University, targets the 'machine' which stops the outer membrane from forming properly.
It works differently to all existing antibiotics and it is hoped that it could lay the foundations for future drugs.
Drug-resistant bacteria
Michael Lobritz, global head infectious diseases at Roche, said: 'Our goal is to contribute new innovations to overcome antimicrobial resistance, one of the biggest infectious disease challenges to public health.'
The phase-three trial, which it is hoped will start later this year or in early 2026, will look at around 400 patients with a carbapenem-resistant Acinetobacter Baumannii (CRAB) infection who will either receive zosuarbalpin or the current standard of care.
It is hoped that the drug will be approved by the end of the decade.
Larry Tsai, senior vice president and global head of immunology and product development at Genentech, a unit of Roche, said that the drug-resistant bacteria 'are present in every country of the world' .
He said that 'the innovative biology involved in this research could potentially reveal new insights into the structure of bacterial membranes, possibly leading to the discovery of new antibiotics in the future'.
Pharmaceutical companies, including Roche, have in the past been unwilling to pursue new antibiotics because of a difficult market in which the drugs are used sparingly to try and avoid resistance.
However, the UN has warned that if nothing is done to address the issue, drug-resistant diseases could cause 10 million deaths each year by 2050 and cause a worldwide financial crash.
'Exciting development'
Dr Alistair Farley, scientific lead at the Ineos Oxford Institute, has welcomed zosurabalpin as an 'exciting development' for the field.
'There is an urgent unmet clinical need to develop new antibiotics against priority pathogens such as CRAB where antimicrobial resistance is a major concern,' he said.
Dr Farley added that it 'may provide a route to the development of new drugs'.
Studies showing that it worked 'extremely well' in test-tubes and mice were published in the journal Nature earlier this year.
Prof Laura Piddock, scientific director of the Global Antibiotic Research and Development Partnership, said at the time that it provided 'definite hope' for other hard-to-treat infections.
'What is exciting about this discovery is that one of the building blocks that are part of the outer part of this bacterial cell is disrupted by this new drug,' Prof Piddock said.
Antimicrobial resistance was declared by world leaders to be 'one of the most urgent global health threats' at the UN General Assembly earlier this year.
The declaration committed members to establish independent panels on antimicrobial resistance, as many have done for climate change, and to reduce deaths linked to resistance by 10 per cent by 2030.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
11 minutes ago
- The Independent
Jeff Bezos' Blue Origin takes 80-year-old adventurer on flight into space
An 80-year-old thrill-seeker, Arvinder 'Arvi' Singh Bahal, was among the crew on the latest rocket ride operated by Jeff Bezos ' Blue Origin. The space tourism mission, known as NS-34, was the 34th flight for the New Shepard programme. The 10-minute journey, which also included cryptocurrency billionaire Justin Sun, launched on Sunday. Sun had previously bid $28 million for his seat on the flight. Watch the video in full above.
The Independent
40 minutes ago
- The Independent
It takes a lot to impress a mature skin beauty writer – but this anti-ageing cream won me over
We're spoiled for choice with doctor-developed skincare: Augustinus Bader, Dr. Barbara Sturm, Dr. Dennis Gross, and 111Skin are just some of the popular brands rooted in their founders' medical expertise. However, before all these popular skincare brands came along, Murad was ahead of its time. Celebrity dermatologist Dr. Howard Murad was among the first dermatologists to start selling clinical skincare products to the general public. Today, his anti-ageing products are so well-loved and trusted that Murad is the number one dermatologist-founded skincare brand in the States. The brand's marketing makes much of the claim that it only uses 'scientifically proven formulas' to create its products, but it's hard to measure up to that promise. When I saw that the brand launched a range of four new SPF moisturisers, with a high level of sunscreen and high-performance actives, I had to see if it really lived up to the hype. Leading the pack is the Murad superactive moisturiser SPF50: brightening, an update to the essential-C day moisturise SPF30 (£69, with a new formula and a new look. This vitamin C-loaded day cream promises to act like a 3-in-1 moisturiser, skin-brightener and sunscreen all in one, and it certainly lives up to the claim. It's so good it's earned itself the top spot in my guide to the best anti-ageing day creams. How I tested To put the new SPF moisturiser to the test, I've been trialling it for six weeks in place of my daily serum, moisturiser and SPF. This was through two heat waves when UV levels were high. During testing, I assessed the moisturiser using the following criteria. Texture: I noted how the formula felt on the skin. Did it feel greasy and heavy, or was it more lightweight? Hydration: And, as a moisturiser, its formula should be hydrating, so I noted how hydrated my skin felt. Additionally, I assessed how well the formula sat beneath my make-up, and whether it left a white cast, as SPFs sometimes can. Results: I looked at how well the cream rejuvenated my skin. Specifically, whether it brightened and evened my skin tone, and had any effect on dark spots, as these are the effects the brand claims the product will have. At the same time, I noted any skin irritation. Ease of use: Murad has introduced new packaging, so I assessed if, and how, this helped with ease of application. Why you can trust IndyBest reviews Sabine Wiesel is a beauty journalist with years of experience trialling and recommending skincare to IndyBest readers. As a woman in her 40s, she has reviewed plenty of neck creams, retinol eye creams and similar products formulated to address the signs of ageing, such as fine lines, dullness and dark spots. With this in mind, she knows which actives to look for, and has a wealth of relevant testing experience. Having tried many anti-ageing day creams for our round-up of the best, Sabine named Murad's superactive moisturiser SPF50 the best on test. This is her full, honest review.
The Independent
2 hours ago
- The Independent
Humans may have hibernation ‘superpowers' in untapped genes, scientists say
The 'superpowers' of hibernating animals are also present in human DNA, according to a pair of recent studies that provide clues to unlocking this potential and opening the door for new diabetes and Alzheimer's treatments. Hibernating animals such as squirrels and bears exhibit incredible resilience, going long periods without food and water and withstanding near-freezing temperatures by slowing down metabolism. They avoid muscle and nerve decay and stay healthy despite massive weight fluctuations. When these animals emerge from hibernation, they appear to recover from dangerous symptoms similar to those seen in people suffering from diabetes, Alzheimer's and stroke. 'If we could regulate our genes a bit more like hibernators, maybe we could overcome type 2 diabetes the same way a hibernator returns from hibernation back to a normal metabolic state,' Elliott Ferris, an author of one of the studies, says. The research focuses on a gene cluster called the 'fat mass and obesity locus', which plays an important role in hibernators. DNA regions near the FTO locus regulate the activities of neighbouring genes, tuning them up or down. They enable hibernators to put on weight before cosying up for winter and allow them to slowly use their fat reserves throughout hibernation, researchers say. 'What's striking about this region is that it is the strongest genetic risk factor for human obesity,' says Chris Gregg, a senior author of one of the studies from the University of Utah Health. When researchers mutated the hibernator-specific gene regions in mice, they noticed changes in their metabolism and weight. Some mutations sped up weight gain while others slowed it down under specific dietary conditions. The mutations also affected the ability of mice to recover body temperature after a hibernation-like state. 'When you knock out one of these elements – this one tiny, seemingly insignificant DNA region – the activity of hundreds of genes changes,' Susan Steinwand, another author of the studies, says. Previous studies show that hibernating animals can reverse neurodegeneration, avoid muscle decay, remain healthy despite massive weight fluctuations, and show improved ageing and longevity. The latest studies suggest we possess the necessary genetic code for hibernator-like superpowers, if we can bypass some of our metabolic switches. 'This work provides a genetic framework for harnessing hibernator adaptations to understand human metabolic control,' researchers say. 'Humans already have the genetic framework,' Dr Steinwand says. 'We just need to identify the control switches for these hibernator traits.' Further studies on these genes and their surrounding DNA regions can help confer similar resilience to humans, scientists say. 'There's potentially an opportunity – by understanding these hibernation-linked mechanisms in the genome – to find strategies to intervene and help with age-related diseases,' Dr Gregg says. 'If that's hidden in the genome that we've already got, we could learn from hibernators to improve our own health.'
